Medication Assisted Treatment (MAT)
Medication assisted treatment (MAT) is the use of pharmacological medications, in combination with counseling and behavioral therapies, to provide a ‘whole patient' approach to the treatment of substance use disorders. Research indicates that a combination of medication and behavioral therapies can successfully treat substance use disorders, and for some people struggling with addiction, MAT can help sustain recovery.
Procedures for Medication-Assisted Treatment of Alcohol or Opioid Dependence in Primary Care provides an introduction to identifying and treating patients with substance use disorders in primary care settings.
The Sublingual and Transmucosal Buprenorphine for Opioid Use Disorder: Review and Update reviews current information on the use of sublingual and transmucosal buprenorphine for the medication-assisted treatment of opioid use disorder. Topics include new formulations of buprenorphine, the effectiveness and safety of buprenorphine treatment, contraindications and cautions (including medication interactions), informed consent and treatment agreements, treatment monitoring, and indications of diversion and misuse.
Developed by the Centers for Medicare & Medicaid Services Health Home Information Resource Center, the Designing Medicaid Health Homes for Individuals with Opioid Dependency: Considerations for States brief, highlights key features of approved health home models from Maryland, Rhode Island, and Vermont that are tailored to individuals with opioid dependency. It identifies important considerations in developing opioid dependence-focused health homes.
Free Online Course about High Risk Opioid Use
This online course, created by the National Institute on Drug Abuse (NIDA) and the Institute for Research, Education, and Training in Addictions (IRETA), features informative graphics, videos and practice scenarios on opioids and the behavior pattern known as “doctor shopping.” Continuing Education Units are available for social workers, counselors, medical professionals, and others.
SAMHSA's Medication for the Treatment of Alcohol Use Disorder: A Brief Guide provides guidance for the use of medication-assisted treatment for alcoholism and alcohol abuse in clinical practice. The guide also summarizes approved medications and discusses screening and patient assessment, treatment planning, and patient monitoring.
SAMHSA's Clinical Use of Extended-Release Injectable Naltrexone in the Treatment of Opioid Use Disorders: A Brief Guide offers guidance on the use of MAT with extended-release injectable naltrexone for the treatment of an opioid use disorder. Covers patient assessment, initiating MAT, monitoring progress and deciding when to end treatment.
Expanding the Use of Medications to Treat Individuals with Substance Use Disorders outlines the lessons learned from a year-long collaborative with safety-net providers to explore the barriers and opportunities for communities to implement use of medications for addictions treatment.
SAMHSA's Opioid Overdose Prevention Toolkit
Equips communities and local governments with material to develop policies and practices to help prevent opioid-related overdoses and deaths. It also addresses issues for first responders, treatment providers, and those recovering from opioid overdose.
Published by the American Society of Addiction Medicine, the Medicaid Benefits for the Treatment of Opioid Use Disorder Nationwide displays state's Medicaid fee-for-service benefit coverage for medications approved to treat opioid dependence.
The Centers for Medicare & Medicaid Services (CMS) released an Informational Bulletin highlighting the use of FDA-approved medications in combination with evidence-based behavioral therapies to help persons with mental health and substance use disorders recover in a safe and cost-effective manner. The bulletin provides background information about medication assisted treatment (MAT), examples of state-based initiatives, and useful resources to help ensure proper delivery of these services.
The American Psychiatric Association conducted a series of webinars with SAMHSA's Providers’ Clinical Support System for Medication Assisted Treatment (PCSS-MAT). Webinar topics include pain management, the psychology of AA, and treatment options.
Advancing Access to Addiction Medications: Implications for Opioid Addiction Treatment
reviews the empirical economic evaluations of medications for the treatment of opioid dependence.
Buprenorphine/Naloxone and Methadone Maintenance Treatment Outcomes for Opioid Analgesic, Heroin, and Combined Users: Findings From Starting Treatment With Agonist Replacement Therapies (START) is a recent study that looks at treatment outcomes versus type of treatment medication used.
Financial Factors and the Implementation of Medications for Treating Opioid Use Disorders examines the relationships between organizational factors and the program-level implementation of MAT, with attention paid to specific sources of funding, organizational structure, and workforce resources.
The Training Tool for Residential Substance Abuse Treatment: Medication Assisted Treatment for Offender Populations from Advocates for Human Potential with a number of partners, including Treatment Alternatives for Safe Communities (TASC), outlines evidence-based practices for using MAT with criminal justice-involved individuals.
SAMHSA's General Principles for the Use of Pharmacological Agents To Treat Individuals With Co-Occurring Mental and Substance Use Disorders provides general principles to assist in the planning, delivery, and evaluation of pharmacologic approaches to support the recovery of individuals with co-occurring mental and substance use disorders.
The ATTC's Medication-Assisted Treatment with Special Populations online training, developed for both non-physician treatment providers and physicians, is designed to enhance professionals' knowledge and skills related to reaching and educating the special populations about MAT and increasing the use of MAT among minority populations.
SAMHSA’s Advisory: An Introduction to Extended-Release Injectable Naltrexone for the Treatment of People with Opioid Dependence overviews extended-release injectable naltrexone, a treatment for people with opioid dependence, and discusses how it differs from other medication-assisted treatments, safety concerns, and consumers most likely to benefit from this treatment.
Read this compilation of essays by individuals in long-term recovery supported by medication assisted treatment developed in partnership with Faces & Voices of Recovery and the National Alliance for Medication Assisted Recovery.
The Rx Database is designed as a desk-top reference of medications commonly used to treat individuals with alcohol, drug and mental health conditions. This searchable database is intended to provide a basic understanding of medication dose, frequency, side effects, emergency conditions, abuse potential, cautions and considerations for special populations (such as pregnant women).
SAMHSA's Medication-Assisted Treatment for Opioid Addiction: Friends and Families is a useful resource for friends and families of individuals struggling with addiction.
SAMHSA’s Treatment Improvement Protocol (TIP) 40: Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction provides information that physicians can use to make practical and informed decisions about the use of buprenorphine to treat opioid addiction.
SAMHSA’s TIP 43: Medication-Assisted Treatment for Opioid Addiction in Opioid Treatment Programs discusses MAT use in addiction treatment programs for opioid dependence.
SAMHSA’s TIP 49: Incorporating Alcohol Pharmacotherapies into Medical Practice provides guidance on implementing alcohol medications into routine medical practice.
The Addiction Technology Transfer Center (ATTC) Network is a SAMHSA-funded network of centers that provides training and technical assistance to help enhance the knowledge, skills, and abilities of the addiction treatment workforce through the dissemination of evidence based practices. The Work force development to increase medication-assisted treatment Services among Minority Populations is an initiative of the ATTC to increase awareness, provide education, and promote access to MAT for African American, American Indian/Alaskan Native; Hispanic/Latino and Asian, Native Hawaiian and other Pacific Islander populations.
SAMHSA’s Division of Pharmacotherapies (DPT) manages the day-to-day regulatory oversight activities necessary to implement SAMHSA regulation 42 CFR Part 8 on the use of FDA-approved opioid agonist medications (methadone, LAAM, and buprenorphine) for addiction treatment. These activities include supporting the certification and accreditation of over 1,000 opioid treatment programs (i.e., methadone clinics) that collectively treat over 200,000 patients annually. DPT also supports the Drug Addiction Treatment Act of 2000 (DATA 2000), which expands the clinical context of medication-assisted opioid addiction treatment by allowing qualified physicians to dispense or prescribe specifically approved Schedule III, IV, and V narcotic medications for the treatment of opioid addiction in treatment settings other than the traditional opioid treatment program.
The Medication Assisted Treatment Implementation Checklist outlines the key questions to consider before engaging in efforts to increase access to medication assisted treatment for addictions.
Financial Factors and the Implementation of Medications of Addiction Treatment examines relationships between organizational factors and the program-level implementation of MAT, with attention paid to specific sources of funding, organizational structure, and workforce resources.
Helpful Resources to Address Discrimination Against People in Medication Assisted Treatment provides useful resources for educating employers, courts and others about medication assisted treatment, including why methadone and buprenorphine do not impair physical or mental functioning when provided to individuals stabilized on the appropriate dose.
Getting Started with Medication Assisted Treatment with Lessons from Advancing Recovery provides information and guidance on how to implement MAT into a drug treatment program. This toolkit shares lessons from several Robert Wood Johnson Foundation Advancing Recovery project grantees to establish MAT programs in their organizations.
SAMHSA's Medication-Assisted Treatment of Opioid Use Disorder Pocket Guide provides guidelines for physicians using medication assisted treatment for patients with opioid use disorder. The guide discusses the various types of approved medications, screening and assessment tools, and best practices for patient care.
The ASAM Standards of Care for the Addiction Specialist Physician address the unique responsibilities borne by a physician who manages or oversees the care of a patient with addiction and related disorders. The Standards are intended to support quality improvement activities conducted by health care provider systems, health care quality entities, medical specialty certification boards, and by individual physicians monitoring their own performance in their own practices.
The ASAM Performance Measures: Applicable to the Addiction Specialist Physician shares clear and broadly accepted performance measures are useful to physicians, patients, purchasers, and others and are now being used across the health care spectrum — in admission, treatment, discharge, consultations, care transitions, and all points in between. The American Society of Addiction Medicine convened an expert panel to develop performance measures for physicians working with patients with substance use disorders.
Prescribers’ Clinical Support System for Opioid Therapies (PCSS-O) is a collaborative project that includes: American Academy of Addiction Psychiatry, American Dental Association, American Medical Association, American Osteopathic Academy of Addiction Medicine, American Psychiatric Association, American Society for Pain Management Nursing, and International Nurses Society on Addictions.These organizations will provide training and education on the safe and effective prescribing of opioid medications in the treatment of pain and/or opioid addiction. The focus of this project is to reach prescribers and/or prescribers-in-training from diverse healthcare professions including physicians, nurses, dentists, physician assistants, and pharmacists to offer free, accessible, evidence-based trainings.
The American Society of Addiction Medicine represents nearly 3,000 physicians dedicated to increasing access and improving quality of addiction treatment, educating physicians and the public, supporting research and prevention, and promoting the appropriate role of physicians in the care of patients with addictions.
The American Association of Addiction Psychiatry is an international organization with approximately 1,000 professional members that educates, influences, and encourages excellence in practice, policy and prevention for the field of addiction psychiatry.